Pomalidomide-C6-PEG3-butyl azide is a specialized E3 Ligase Ligand-Linker Conjugate designed for advanced PROTAC (Proteolysis Targeting Chimera) research and drug discovery. This compound features pomalidomide, a well-characterized cereblon (CRBN) E3 ligase ligand, tethered via a C6-PEG3-butyl azide linker. The azide functional group facilitates bioorthogonal click chemistry, enabling efficient attachment to various targeting ligands or warheads. As a crucial component in the development of PROTACs, Pomalidomide-C6-PEG3-butyl azide enables researchers to harness the ubiquitin-proteasome pathway for targeted protein degradation. Ideal for assembling versatile PROTAC libraries, this conjugate supports the rapid development of next-generation therapeutics aimed at undruggable targets in cancer, neurological disorders, and immune diseases. Optimize your PROTAC workflows with this high-purity, ready-to-conjugate E3 ligase ligand-linker designed for innovative small-molecule degrader research.
* For research and manufacturing use only. Not for human or clinical use.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
Background Introduction
Pomalidomide-C6-PEG3-butyl azide is a specialized E3 ligase ligand-linker conjugate, designed for use in Proteolysis Targeting Chimera (PROTAC) and targeted protein degradation research. It incorporates the immunomodulatory drug (IMiD) pomalidomide, which binds to the CRBN E3 ubiquitin ligase, with a C6-PEG3 linker ending in a reactive butyl azide group. This modular structure facilitates the development of bifunctional molecules through click chemistry, enabling the precise targeting and degradation of specific proteins.
Mechanism
The mechanism of Pomalidomide-C6-PEG3-butyl azide is based on the PROTAC strategy. The pomalidomide moiety acts as a ligand for the CRBN E3 ubiquitin ligase, recruiting it to the target protein of interest. The C6-PEG3 flexible linker provides optimal spatial orientation and solubility, while the terminal butyl azide enables bioorthogonal conjugation with alkyne-tagged targeting ligands via copper-catalyzed azide-alkyne cycloaddition (CuAAC). Once a bifunctional PROTAC is synthesized using this conjugate, it brings the E3 ligase and target protein into proximity, leading to ubiquitination and subsequent proteasomal degradation of the target protein within the cell.
Applications
Pomalidomide-C6-PEG3-butyl azide is widely used in drug discovery and chemical biology for the synthesis of CRBN-based PROTACs aimed at selective protein degradation. It enables rapid assembly of customized PROTAC libraries via click chemistry, accelerating the exploration of targeted protein knockdown in cancer, neurodegenerative diseases, and other therapeutic areas. The product is ideal for researchers developing next-generation degraders, validating novel drug targets, or investigating the biology of E3 ligase-mediated ubiquitination pathways.
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
Please contact us with any specific requirements and we will get back to you as soon as possible.